基于症状、生物标志物和血清药物浓度增加英夫利西单抗剂量并未提高活动性管腔型克罗恩病患者的临床、内镜和免激素缓解率
这项双盲、随机、探索性试验纳入122例生物制剂初治的活动性克罗恩病患者,从治疗第14周起按1:1:1分为三组,分别根据症状、生物标志物和/或血清英夫利西单抗浓度增加剂量(DIS1组)、根据相同标准从5 mg/kg增至10 mg/kg(DIS2组)、或仅根据症状增至10 mg/kg(对照组)。主要终点为第22至54周持续免激素临床缓解且第54周无溃疡,三组分别有33%、27%和40%达到该终点(P = .50)。
要点
- 基于症状、生物标志物和血清浓度的剂量强化策略未提高持续免激素临床和内镜缓解率。
- 三组主要终点达成率分别为DIS1组33%、DIS2组27%、对照组40%(P = .50)。
- 该研究为探索性试验,结论需进一步研究验证。
核心结论
- 在活动性克罗恩病的前瞻性随机探索性试验中,基于症状、生物标志物和血清药物浓度联合增加英夫利西单抗剂量,并未比仅基于症状增加剂量使更大比例患者达到免激素临床缓解。
研究设计与样本
- 双盲、随机、探索性试验,纳入122例生物制剂初治的活动性克罗恩病成年患者(女性71例,中位年龄29.8岁),2012年7月至2015年9月在欧洲27个中心接受英夫利西单抗联合免疫抑制剂诱导治疗。
- 治疗第14周按1:1:1随机分为三组:DIS1组根据症状、生物标志物和/或血清英夫利西单抗浓度,以2.5 mg/kg为步长增加剂量(最多2次);DIS2组根据相同标准从5 mg/kg增至10 mg/kg;对照组仅根据临床症状增至10 mg/kg。
- 主要终点为第22至54周持续免激素临床缓解(克罗恩病活动指数<150)且第54周无溃疡。
主要发现
- 达到主要终点者:DIS1组45例中15例(33%),DIS2组37例中10例(27%),对照组40例中16例(40%)(P = .50)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic threshold. We performed a prospective, randomized trial to determine whether therapeutic drug monitoring (TDM) to maintain serum levels of infliximab above 3 μg/mL produced higher rates of clinical and endoscopic remission than adapting dose based only on symptoms. METHODS: We performed a double-blind trial in which 122 biologic-naïve adult patients with active CD (71 female, median age 29.8 years) received induction treatment with infliximab in combination with an immunosuppressant, from July 2012 through September 2015 at 27 centers in Europe. At week 14 of treatment, patients were randomly assigned (1:1:1) to 3 infliximab maintenance groups: dose increases (2 maximum) in steps of 2.5 mg/kg based on clinical symptoms and biomarker analysis and/or serum infliximab concentrations (dose intensification strategy [DIS]1 group); dose increase from 5 to 10 mg/kg based on the same criteria (DIS2 group); dose increase to 10 mg/kg based on clinical symptoms alone (controls). Patients' CD activity index scores, levels of C-reactive protein, fecal levels of calprotectin, and serum concentrations of infliximab were determined at baseline and at weeks 2, 4, 6, 12, and 14 of treatment, and then every 4 weeks thereafter until week 54. The primary endpoint was sustained corticosteroid-free clinical remission (CD activity index <150) from weeks 22 through 54 with no ulcers at week 54. RESULTS: The primary endpoint was reached by 15 (33%) of 45 patients in the DIS1 group, 10 (27%) of 37 patients in the DIS2 group, and 16 (40%) of 40 patients in the control group (P = .50). CONCLUSIONS: In a prospective randomized exploratory trial of patients with active CD, we found increasing dose of infliximab based on a combination of symptoms, biomarkers, and serum drug concentrations does not lead to corticosteroid-free clinical remission in a larger proportion of patients than increasing dose based on symptoms alone. EUDRACT NUMBER: 2011-003038-14.
引用
- D'Haens G, Vermeire S, Lambrecht G, et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018. PMID: 29317275. doi:10.1053/j.gastro.2018.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。